Dimensional Fund Advisors LP Trims Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Dimensional Fund Advisors LP reduced its holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 15.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,732,378 shares of the company's stock after selling 321,867 shares during the period. Dimensional Fund Advisors LP owned about 1.91% of Caribou Biosciences worth $2,755,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Milestone Asset Management LLC grew its holdings in Caribou Biosciences by 5.6% in the fourth quarter. Milestone Asset Management LLC now owns 163,789 shares of the company's stock valued at $260,000 after purchasing an additional 8,662 shares during the period. American Century Companies Inc. grew its holdings in Caribou Biosciences by 9.2% in the fourth quarter. American Century Companies Inc. now owns 159,822 shares of the company's stock valued at $254,000 after purchasing an additional 13,421 shares during the period. Envestnet Asset Management Inc. grew its holdings in Caribou Biosciences by 43.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 46,301 shares of the company's stock valued at $74,000 after purchasing an additional 14,021 shares during the period. Intech Investment Management LLC boosted its stake in shares of Caribou Biosciences by 69.4% in the fourth quarter. Intech Investment Management LLC now owns 37,478 shares of the company's stock worth $60,000 after acquiring an additional 15,352 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of Caribou Biosciences by 12.0% in the fourth quarter. Barclays PLC now owns 145,417 shares of the company's stock worth $231,000 after acquiring an additional 15,578 shares during the last quarter. 77.51% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price target (down from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Caribou Biosciences presently has an average rating of "Buy" and a consensus price target of $7.40.

Caribou Biosciences Stock Performance

Shares of NASDAQ:CRBU traded up $0.11 during trading on Monday, reaching $1.05. The stock had a trading volume of 1,090,592 shares, compared to its average volume of 1,512,766. The business has a fifty day moving average price of $0.86 and a 200-day moving average price of $1.41. The stock has a market cap of $97.66 million, a PE ratio of -0.64 and a beta of 2.36. Caribou Biosciences, Inc. has a 1-year low of $0.66 and a 1-year high of $3.45.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.43). Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.35 million for the quarter, compared to analyst estimates of $1.48 million. Sell-side analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.